Physician profile
Dino J Delaportas
NPI 1639124159
$478,093.04
in general payments reported to CMS, 2019-2025
33 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205K · 2020: $35K · 2021: $42K · 2022: $123K · 2023: $48K · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $4,205 · Travel and Lodging: $3,187 · Consulting Fee: $2,125 · Education: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,249.49 |
| Food and Beverage | $4,205.47 |
| Travel and Lodging | $3,186.50 |
| Consulting Fee | $2,125.00 |
| Education | $1,251.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $110,863.95 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Allergan, INC. | $97,650.95 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $87,247.06 | 2021-2025 | Rebyota |
| Paratek Pharmaceuticals, INC. | $71,618.64 | 2019-2025 | Nuzyra |
| Cumberland Pharmaceuticals, INC. | $39,425.19 | 2019-2025 | Vibativ, Caldolor |
| Merck Sharp & Dohme LLC | $31,881.31 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $24,078.75 | 2019-2025 | Arikayce |
| Abbvie INC. | $9,235.22 | 2021-2022 | |
| Shionogi INC | $3,384.17 | 2021-2025 | Fetroja |
| Baudax Bio INC. | $1,124.36 | 2020-2021 | |
| Organogenesis INC. | $292.49 | 2019-2025 | Puraply Wound Matrix, Cygnus Dual, Cygnus Matrix |
| Smith+Nephew, INC. | $286.11 | 2019-2025 | Collagenase Santyl, Regranex |
| La Jolla Pharmaceutical Company | $216.83 | 2020-2024 | Xacduro, Xerava |
| Astellas Pharma US INC | $170.78 | 2020 | |
| Lifenet Health | $112.71 | 2023-2024 | Theragenesis Wound Matrix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accelerate Diagnostics INC. | $69.25 | 2019 | |
| Bioventus LLC | $61.98 | 2022-2023 | Sonicone Clinic |
| Gilead Sciences, INC. | $61.27 | 2021 | |
| Misonix INC | $55.06 | 2021 | |
| Ovik Health, LLC | $35.09 | 2020 | |
| Cipla USA INC. | $34.67 | 2021 | |
| Grt US Holding, INC. | $28.36 | 2022 | |
| Reprise Biomedical, INC. | $22.56 | 2024 | Miro3d |
| Invivyd INC | $22.20 | 2024 | Pemgarda |
| Mylan Specialty L.P. | $19.26 | 2019 | |
| Hartmann USA, INC. | $17.20 | 2022 | |
| Vyera Pharmaceuticals, LLC | $17.09 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Ethicon US, LLC | $15.26 | 2019 | |
| Glaxosmithkline, LLC. | $14.00 | 2020 | |
| Mckesson Patient Care Solutions INC. | $12.48 | 2019 | |
| Kerecis Limited | $2.68 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dino Delaportas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.